Myelodysplastic syndromes (MDS) are age-dependent stem cell malignancies that share biological features of activated adaptive immune response and ineffective hematopoiesis. Here we report that myeloid-derived suppressor cells (MDSC), which are classically linked to immunosuppression, inflammation, and cancer, were markedly expanded in the bone marrow of MDS patients and played a pathogenetic role in the development of ineffective hematopoiesis. These clonally distinct MDSC overproduce hematopoietic suppressive cytokines and function as potent apoptotic effectors targeting autologous hematopoietic progenitors. Using multiple transfected cell models, we found that MDSC expansion is driven by the interaction of the proinflammatory molecule S100A9 with CD33. These 2 proteins formed a functional ligand/receptor pair that recruited components to CD33’s immunoreceptor tyrosine-based inhibition motif (ITIM), inducing secretion of the suppressive cytokines IL-10 and TGF-β by immature myeloid cells.
Xianghong Chen, Erika A. Eksioglu, Junmin Zhou, Ling Zhang, Julie Djeu, Nicole Fortenbery, Pearlie Epling-Burnette, Sandra Van Bijnen, Harry Dolstra, John Cannon, Je-in Youn, Sarah S. Donatelli, Dahui Qin, Theo De Witte, Jianguo Tao, Huaquan Wang, Pingyan Cheng, Dmitry I. Gabrilovich, Alan List, Sheng Wei
Title and authors | Publication | Year |
---|---|---|
The Emerging Role of CD8+ T Cells in Shaping Treatment Outcomes of Patients with MDS and AML
Tasis A, Spyropoulos T, Mitroulis I |
Cancers | 2025 |
Myeloid-derived suppressor cells in cancer and cancer therapy.
Lasser SA, Ozbay Kurt FG, Arkhypov I, Utikal J, Umansky V |
Nature reviews. Clinical oncology | 2024 |
Engagement of sialylated glycans with Siglec receptors on suppressive myeloid cells inhibits anticancer immunity via CCL2.
Wieboldt R, Sandholzer M, Carlini E, Lin CW, Börsch A, Zingg A, Lardinois D, Herzig P, Don L, Zippelius A, Läubli H, Mantuano NR |
Cellular & molecular immunology | 2024 |
First‐in‐human study of JNJ‐67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome
Narayan R, Piérola AA, Donnellan WB, Yordi AM, Abdul\u2010Hay M, Platzbecker U, Subklewe M, Kadia TM, Alonso\u2010Domínguez JM, McCloskey J, Bradford K, Curtis M, Daskalakis N, Guttke C, Safer K, Hiebert B, Murphy J, Li X, Duchin K, Esteban D |
Clinical and Translational Science | 2024 |
MDSC expansion during HIV infection: regulators, ART and immune reconstitution.
Yaseen MM, Abuharfeil NM, Darmani H |
Genes and Immunity | 2024 |
Granzymes in health and diseases: the good, the bad and the ugly.
Cigalotto L, Martinvalet D |
Frontiers in immunology | 2024 |
S100A9: The Unusual Suspect Connecting Viral Infection and Inflammation.
Boucher J, Gilbert C, Bose S, Tessier PA |
Journal of immunology (Baltimore, Md. : 1950) | 2024 |
Immune-monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortium.
Tentori CA, Zhao LP, Tinterri B, Strange KE, Zoldan K, Dimopoulos K, Feng X, Riva E, Lim B, Simoni Y, Murthy V, Hayes MJ, Poloni A, Padron E, Cardoso BA, Cross M, Winter S, Santaolalla A, Patel BA, Groarke EM, Wiseman DH, Jones K, Jamieson L, Manogaran C, Daver N, Gallur L, Ingram W, Ferrell PB, Sockel K, Dulphy N, Chapuis N, Kubasch AS, Olsnes AM, Kulasekararaj A, De Lavellade H, Kern W, Van Hemelrijck M, Bonnet D, Westers TM, Freeman S, Oelschlaegel U, Valcarcel D, Raddi MG, Grønbæk K, Fontenay M, Loghavi S, Santini V, Almeida AM, Irish JM, Sallman DA, Young NS, van de Loosdrecht AA, Adès L, Della Porta MG, Cargo C, Platzbecker U, Kordasti S |
HemaSphere | 2024 |
Targeting MCL1-driven anti-apoptotic pathways overcomes blast progression after hypomethylating agent failure in chronic myelomonocytic leukemia
Montalban-Bravo G, Thongon N, Rodriguez-Sevilla JJ, Ma F, Ganan-Gomez I, Yang H, Kim YJ, Adema V, Wildeman B, Tanaka T, Darbaniyan F, Al-Atrash G, Dwyer K, Loghavi S, Kanagal-Shamanna R, Song X, Zhang J, Takahashi K, Kantarjian H, Garcia-Manero G, Colla S |
Cell reports. Medicine | 2024 |
Glioma-Associated Sialoglycans Drive the Immune Suppressive Phenotype and Function of Myeloid Cells
Cornelissen LA, Santegoets KC, Kers-Rebel ED, Bossmann SA, Ter Laan M, Granado D, Adema GJ |
Pharmaceutics | 2024 |
Prototypical innate immune mechanism hijacked by leukemia-initiating mutant stem cells for selective advantage and immune evasion in Ptpn11-associated juvenile myelomonocytic leukemia
Qu CK, Zheng H, Zhao P, Tan Z, Yu WM, Werner J, Stieglitz E, Porter C, Chandrakasan S, Wechsler D, Mendez-Ferrer S |
Research Square | 2024 |
Implications for Metabolic Disturbances in Myelodysplastic Syndromes
McGraw KL, Larson DR |
Seminars in hematology | 2024 |
Monocytes generated by interleukin-6-treated human hematopoietic stem and progenitor cells secrete calprotectin that inhibits erythropoiesis
Marchand V, Laplane L, Valensi L, Plo I, Aglave M, Silvin A, Pasquier F, Porteu F, Vainchenker W, Selimoglu-Buet D, Droin N, Raslova H, Marcel V, Diaz JJ, Fontenay M, Solary E |
iScience | 2024 |
Oxidized Mitochondrial DNA Engages TLR9 to Activate the NLRP3 Inflammasome in Myelodysplastic Syndromes
Ward GA, Dalton RP III, Meyer BS, McLemore AF, Aldrich AL, Lam NB, Onimus AH, Vincelette ND, Trinh TL, Chen X, Calescibetta AR, Christiansen SM, Hou HA, Johnson JO, Wright KL, Padron E, Eksioglu EA, List AF |
International journal of molecular sciences | 2023 |
A Killer Disarmed: Natural Killer Cell Impairment in Myelodysplastic Syndrome.
Arellano-Ballestero H, Sabry M, Lowdell MW |
Cells | 2023 |
The Role of BCL-2 and PD-1/PD-L1 Pathway in Pathogenesis of Myelodysplastic Syndromes
Kuszczak B, Wróbel T, Wicherska-Pawłowska K, Rybka J |
International journal of molecular sciences | 2023 |
The roles of toll-like receptor 4, CD33, CD68, CD69, or CD147/EMMPRIN for monocyte activation by the DAMP S100A8/S100A9
Möller A, Jauch-Speer SL, Gandhi S, Vogl T, Roth J, Fehler O |
Frontiers in immunology | 2023 |
Modulation of T-cell function by myeloid-derived suppressor cells in hematological malignancies
Bhardwaj V, Ansell SM |
Frontiers in Cell and Developmental Biology | 2023 |
Immunogenic Cell Death in Hematological Malignancy Therapy
Liu Z, Xu X, Liu K, Zhang J, Ding D, Fu R |
Advanced Science | 2023 |
High BM plasma S100A8/A9 is associated with a perturbed microenvironmentand poor prognosis in myelodysplastic syndromes
Wang YH, Lin CC, Yao CY, Amaral FM, Yu SC, Kao CJ, Shih PT, Hou HA, Chou WC, Tien HF |
Blood Advances | 2023 |
Role of innate immunological/inflammatory pathways in myelodysplastic syndromes and AML: a narrative review
Vegivinti CT, Keesari PR, Veeraballi S, Martins Maia CM, Mehta AK, Lavu RR, Thakur RK, Tella SH, Patel R, Kakumani VK, Pulakurthi YS, Aluri S, Aggarwal RK, Ramachandra N, Zhao R, Sahu S, Shastri A, Verma A |
Experimental Hematology and Oncology | 2023 |
Immune escape and resistance to immunotherapy in mismatch repair deficient tumors
Mestrallet G, Brown M, Bozkus CC, Bhardwaj N |
Frontiers in immunology | 2023 |
The recent progress of myeloid‐derived suppressor cell and its targeted therapies in cancers
Ren R, Xiong C, Ma R, Wang Y, Yue T, Yu J, Shao B |
2023 | |
Immune dysregulation and potential targeted therapy in myelodysplastic syndrome
Zhang X, Yang X, Ma L, Zhang Y, Wei J |
Therapeutic Advances in Hematology | 2023 |
S100A8 and S100A9 in Hematologic Malignancies: From Development to Therapy
Razmkhah F, Kim S, Lim S, Dania AJ, Choi J |
International journal of molecular sciences | 2023 |
Immune checkpoints represent a promising breakthrough in targeted therapy and prognosis of myelodysplastic syndrome
Guo X, Yu S, Ren X, Li L |
Heliyon | 2023 |
SRSF2 mutation reduces polycythemia and impairs hematopoietic progenitor functions in JAK2V617F-driven myeloproliferative neoplasm
Yang Y, Abbas S, Sayem MA, Dutta A, Mohi G |
Blood Cancer Journal | 2023 |
A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents.
Bewersdorf JP, Shallis RM, Sharon E, Park S, Ramaswamy R, Roe CE, Irish JM, Caldwell A, Wei W, Yacoub A, Madanat YF, Zeidner JF, Altman JK, Odenike O, Yerrabothala S, Kovacsovics T, Podoltsev NA, Halene S, Little RF, Piekarz R, Gore SD, Kim TK, Zeidan AM |
Annals of Hematology | 2023 |
TIRAP drives myelosuppression through an Ifnγ–Hmgb1 axis that disrupts the endothelial niche in mice
A Gopal, R Ibrahim, M Fuller, P Umlandt, J Parker, J Tran, L Chang, J Wegrzyn-Woltosz, J Lam, J Li, M Lu, A Karsan |
Journal of Experimental Medicine | 2022 |
SF3B1 mutations induce pathogenic activation of targetable inflammatory immune signaling in MDS
Gaurav Choudhary, Andrea Pellagatti, Bogos Agianian, Molly Smith, Tushar Bhagat, Shanisha Gordon-Mitchell, Sanjay Pandey, Nishi Shah, Srinivas Aluri, Leya Schwartz, Violetta Steeples, Robert Booher, Murali Ramachandra, Maria Samson, Milagros Carbajal, Kith Pradhan, Teresa Bowman, Manoj M. Pillai, Britta Will, Amittha Wickrema, Aditi Shastri, Robert Martell, Ulrich Steidl, Evripidis Gavathiotis, Jacqueline Boultwood, Daniel Starczynowski, Amit Verma |
eLife | 2022 |
Murine myeloid derived suppressor cells possess a range of suppressive mechanisms—Granzyme B is not among them
E Tibbs, X Cao |
Cancer Immunology, Immunotherapy | 2022 |
A Structural Perspective on Calprotectin as a Ligand of Receptors Mediating Inflammation and Potential Drug Target
V Garcia, Y Perera, W Chazin |
Biomolecules | 2022 |
Emerging Canonical and Non-Canonical Roles of Granzyme B in Health and Disease
E Tibbs, X Cao |
Cancers | 2022 |
Emerging immuno-oncology targets in Myelodysplastic Syndromes (MDS)
M Mann, A Brunner |
Current Problems in Cancer | 2022 |
Microenvironmental Features Driving Immune Evasion in Myelodysplastic Syndromes and Acute Myeloid Leukemia
Barakos GP, Hatzimichael E |
Diseases | 2022 |
Inflammasome Activation in Myeloid Malignancies-Friend or Foe?
Andina N, Bonadies N, Allam R |
Frontiers in Cell and Developmental Biology | 2022 |
S100A9-CXCL12 activation in BRCA1-mutant breast cancer promotes an immunosuppressive microenvironment associated with resistance to immunotherapy
Li J, Shu X, Xu J, Su SM, Chan UI, Mo L, Liu J, Zhang X, Adhav R, Chen Q, Wang Y, An T, Zhang X, Lyu X, Li X, Lei JH, Miao K, Sun H, Xing F, Zhang A, Deng C, Xu X |
Nature Communications | 2022 |
Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia
Yang X, Ma L, Zhang X, Huang L, Wei J |
Experimental Hematology and Oncology | 2022 |
Immunodepletion of MDSC by AMV564, a novel bivalent, bispecific CD33/CD3 T cell engager, ex vivo in MDS and melanoma
Cheng P, Chen X, Dalton R, Calescibetta A, So T, Gilvary D, Ward G, Smith V, Eckard S, Fox JA, Guenot J, Markowitz J, Cleveland JL, Wright KL, List AF, Wei S, Eksioglu EA |
Molecular Therapy | 2022 |
Somatic gene mutations expose cytoplasmic DNA to co-opt the cGAS-STING-NLRP3 axis in Myelodysplastic Syndromes
Amy F McLemore, Hsin-An Hou, Benjamin S Meyer, Nghi B. Lam, Grace A. Ward, Amy Aldrich, Matthew A. Rodrigues, Alexis Vedder, Ling Zhang, Eric Padron, Nicole Vincelette, David Sallman, Omar Abdel-Wahab, Alan List, Kathy L McGraw |
JCI Insight | 2022 |
The Innate Immune Protein Calprotectin Interacts With and Encases Biofilm Communities of Pseudomonas aeruginosa and Staphylococcus aureus
Baishya J, Everett JA, Chazin WJ, Rumbaugh KP, Wakeman CA |
Frontiers in Cellular and Infection Microbiology | 2022 |
Cooperation between KDM6B overexpression and TET2 deficiency in the pathogenesis of chronic myelomonocytic leukemia.
Wei Y, Kanagal-Shamanna R, Zheng H, Bao N, Lockyer PP, Class CA, Darbaniyan F, Lu Y, Lin K, Yang H, Montalban-Bravo G, Ganan-Gomez I, Soltysiak KA, Do KA, Colla S, Garcia-Manero G |
Leukemia | 2022 |
The immunomodulatory role of all-trans retinoic acid in tumor microenvironment.
Bi G, Liang J, Bian Y, Shan G, Besskaya V, Wang Q, Zhan C |
Clinical and Experimental Medicine | 2022 |
Myeloid-derived suppressor cells in hematologic malignancies: two sides of the same coin.
Yu S, Ren X, Li L |
Experimental Hematology and Oncology | 2022 |
Diagnosis of Myelodysplastic Syndromes: From Immunological Observations to Clinical Applications.
Simoni Y, Chapuis N |
2022 | |
Myeloid-Derived Suppressor Cells: New Insights into the Pathogenesis and Therapy of MDS
Velegraki M, Stiff A, Papadaki HA, Li Z |
Journal of Clinical Medicine | 2022 |
Pharmacological modulation of myeloid-derived suppressor cells to dampen inflammation.
van Geffen C, Heiss C, Deißler A, Kolahian S |
Frontiers in immunology | 2022 |
New Perspectives on Myeloid-Derived Suppressor Cells and Their Emerging Role in Haematology
Bizymi N, Matthaiou AM, Matheakakis A, Voulgari I, Aresti N, Zavitsanou K, Karasachinidis A, Mavroudi I, Pontikoglou C, Papadaki HA |
Journal of Clinical Medicine | 2022 |
Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy.
Wu Y, Yi M, Niu M, Mei Q, Wu K |
Molecular Cancer | 2022 |
A phase I/II multicenter, open-label, dose escalation and randomized trial of BI 836858 in patients with low- or intermediate-1-risk myelodysplastic syndrome.
Komrokji RS, Carraway HE, Germing U, Wermke M, Zeidan AM, Fu E, Rüter B, Burkard U, Osswald A, Foran JM |
Haematologica | 2022 |
Immune Modulation by Myeloid-Derived Suppressor Cells in Diabetic Kidney Disease
Hsieh CC, Chang CC, Hsu YC, Lin CL |
International journal of molecular sciences | 2022 |
The prognostic effects of circulating myeloid-derived suppressor cells in non-small cell lung cancer: systematic review and meta-analysis.
Bronte G, Calabrò L, Olivieri F, Procopio AD, Crinò L |
Clinical and Experimental Medicine | 2022 |
Bone Marrow Immune Microenvironment in Myelodysplastic Syndromes
Kouroukli O, Symeonidis A, Foukas P, Maragkou MK, Kourea EP |
Cancers | 2022 |
Biological drivers of clinical phenotype in myelofibrosis.
Mascarenhas J, Gleitz HFE, Chifotides HT, Harrison CN, Verstovsek S, Vannucchi AM, Rampal RK, Kiladjian JJ, Vainchenker W, Hoffman R, Schneider RK, List AF |
Leukemia | 2022 |
IRAK1 and IRAK4 as emerging therapeutic targets in hematologic malignancies
J Bennett, DT Starczynowski |
Current Opinion in Hematology | 2021 |
Crucial roles of different RNA-binding hnRNP proteins in Stem Cells
W Xie, H Zhu, M Zhao, L Wang, S Li, C Zhao, Y Zhou, B Zhu, X Jiang, W Liu, C Ren |
International journal of biological sciences | 2021 |
Constitutively Activated DAP12 Induces Functional Anti-Tumor Activation and Maturation of Human Monocyte-Derived DC
R Dalton, A Calescibetta, JM Zhou, M Maurin, G Ward, TL Trinh, N Tu, D Gilvary, X Chen, P Cheng, E Kostenko, S Wei, KL Wright, EA Eksioglu |
International journal of molecular sciences | 2021 |
Inflammation-Induced Tumorigenesis and Metastasis
S Hibino, T Kawazoe, H Kasahara, S Itoh, T Ishimoto, M Sakata-Yanagimoto, K Taniguchi |
International journal of molecular sciences | 2021 |
COVID-19 is a systemic vascular hemopathy: insight for mechanistic and clinical aspects
DM Smadja, SJ Mentzer, M Fontenay, MA Laffan, M Ackermann, J Helms, D Jonigk, R Chocron, GB Pier, N Gendron, S Pons, JL Diehl, C Margadant, C Guerin, EJ Huijbers, A Philippe, N Chapuis, P Nowak-Sliwinska, C Karagiannidis, O Sanchez, P Kümpers, D Skurnik, AM Randi, AW Griffioen |
Angiogenesis | 2021 |
The impact of metal availability on immune function during infection
AJ Monteith, EP Skaar |
Trends in endocrinology and metabolism: TEM | 2021 |
S100A9 Activates the Immunosuppressive Switch Through the PI3K/Akt Pathway to Maintain the Immune Suppression Function of Testicular Macrophages
ZP Fan, ML Peng, YY Chen, YZ Xia, CY Liu, K Zhao, HP Zhang |
Frontiers in immunology | 2021 |
The Role and Therapeutic Targeting of JAK/STAT Signaling in Glioblastoma
A Ou, M Ott, D Fang, AB Heimberger |
Cancers | 2021 |
Interaction Networks Converging on Immunosuppressive Roles of Granzyme B: Special Niches Within the Tumor Microenvironment
W Wang, R Zou, Y Qiu, J Liu, Y Xin, T He, Z Qiu |
Frontiers in immunology | 2021 |
S100A8/A9 in COVID-19 pathogenesis: Impact on clinical outcomes
L Mellett, SA Khader |
Cytokine & Growth Factor Reviews | 2021 |
Myeloid-Derived Suppressor Cells and Mesenchymal Stem/Stromal Cells in Myeloid Malignancies
S Kapor, JF Santibanez |
Journal of Clinical Medicine | 2021 |
Increased Circulating CD4+CXCR5+ Cells and IgG4 Levels in Patients with Myelodysplastic Syndrome with Autoimmune Diseases
N Xiao, X He, H Niu, H Yu, N Cui, H Li, L Yan, Z Shao, L Xing, H Wang, S Li |
Journal of Immunology Research | 2021 |
Regulation of prognosis-related Siglecs in the glioma microenvironment
R Mao, L Zhou, Y Yang, P Wang, H Lin, J Zheng, G Lv, D Zhou |
Journal of Cancer Research and Clinical Oncology | 2021 |
Increased Circulating of CD54highCD181low Neutrophils in Myelodysplastic Syndrome
L Yang, H Li, Y Liu, X Xie, H Zhang, H Niu, Z Shao, L Xing, H Wang |
Frontiers in Oncology | 2021 |
Immune checkpoint blockade in triple negative breast cancer influenced by B cells through myeloid-derived suppressor cells
A Vito, O Salem, N El-Sayes, IP MacFawn, AL Portillo, K Milne, D Harrington, AA Ashkar, Y Wan, ST Workenhe, BH Nelson, TC Bruno, KL Mossman |
2021 | |
Calprotectin: from biomarker to biological function
A Jukic, L Bakiri, EF Wagner, H Tilg, TE Adolph |
Gut | 2021 |
Pathogenic Roles of S100A8 and S100A9 Proteins in Acute Myeloid and Lymphoid Leukemia: Clinical and Therapeutic Impacts
J Mondet, S Chevalier, P Mossuz |
Molecules (Basel, Switzerland) | 2021 |
From Immune Dysregulations to Therapeutic Perspectives in Myelodysplastic Syndromes: A Review
T Comont, E Treiner, F Vergez |
Diagnostics | 2021 |
Therapeutic targeting of the inflammasome in myeloid malignancies
S Chakraborty, LC Shapiro, S de Oliveira, B Rivera-Pena, A Verma, A Shastri |
Blood Cancer Journal | 2021 |
Suprabasin—A Review
M Pribyl, Z Hodny, I Kubikova |
Genes & development | 2021 |
Immune Therapies for Myelodysplastic Syndromes and Acute Myeloid Leukemia
S Kapoor, G Champion, A Basu, A Mariampillai, MJ Olnes |
Cancers | 2021 |
Sequential CRISPR gene editing in human iPSCs charts the clonal evolution of myeloid leukemia and identifies early disease targets
T Wang, AR Pine, AG Kotini, H Yuan, L Zamparo, DT Starczynowski, C Leslie, EP Papapetrou |
Cell Stem Cell | 2021 |
Nature or Nurture? Role of the Bone Marrow Microenvironment in the Genesis and Maintenance of Myelodysplastic Syndromes
SA Mian, D Bonnet |
Cancers | 2021 |
Oxidized mitochondrial DNA released after inflammasome activation is a disease biomarker for myelodysplastic syndromes
GA Ward, KL McGraw, F Abbas-Aghababazadeh, BS Meyer, AF McLemore, ND Vincelette, NB Lam, AL Aldrich, NH Ali, E Padron, J Pinilla-Ibarz, E Masala, V Santini, O Kosmider, M Fontenay, P Fenaux, J Johnson, BL Fridley, AF List |
Blood Advances | 2021 |
Landscape of Myeloid-derived Suppressor Cell in Tumor Immunotherapy
Z Hao, R Li, Y Wang, S Li, Z Hong, Z Han |
Biomarker Research | 2021 |
Current Limitations and Perspectives of Chimeric Antigen Receptor-T-Cells in Acute Myeloid Leukemia
M Maucher, M Srour, S Danhof, H Einsele, M Hudecek, I Yakoub-Agha |
Cancers | 2021 |
CD123-Directed Bispecific Antibodies for Targeting MDS Clones and Immunosuppressive Myeloid-Derived Suppressor Cells (MDSC) in High-Risk Adult MDS Patients
Uckun FM, Watts J |
2021 | |
Stem Cells in the Myelodysplastic Syndromes
Zhan D, Park CY |
2021 | |
Mesenchymal stromal cells shape the MDS microenvironment by inducing suppressive monocytes that dampen NK cell function
Dhifaf Sarhan, Jinhua Wang, Upasana Sunil Arvindam, Caroline Hallstrom, Michael R. Verneris, Bartosz Grzywacz, Erica Warlick, Bruce R. Blazar, Jeffrey S. Miller |
JCI Insight | 2020 |
Aberrantly elevated suprabasin in the bone marrow as a candidate biomarker of advanced disease state in myelodysplastic syndromes
M Pribyl, S Hubackova, A Moudra, M Vancurova, H Polackova, T Stopka, A Jonasova, R Bokorova, O Fuchs, J Stritesky, B Salovska, J Bartek, Z Hodny |
Molecular Oncology | 2020 |
Mass cytometry defines distinct immune profile in germinal center B-cell lymphomas
M Roussel, F Lhomme, CE Roe, T Bartkowiak, P Gravelle, C Laurent, T Fest, JM Irish |
Cancer Immunology, Immunotherapy | 2020 |
The Engagement Between MDSCs and Metastases: Partners in Crime
R Trovato, S Canè, V Petrova, S Sartoris, S Ugel, FD Sanctis |
Frontiers in Oncology | 2020 |
Contribution of Aberrant Toll Like Receptor Signaling to the Pathogenesis of Myelodysplastic Syndromes
LC Paracatu, LG Schuettpelz |
Frontiers in immunology | 2020 |
Immunotherapy in Myeloproliferative Diseases
LM Braun, R Zeiser |
Cells | 2020 |
S100-Alarmins Are Essential Pilots of Postnatal Innate Immune Adaptation
D Viemann |
Frontiers in immunology | 2020 |
Myelodysplastische Syndrome
A Giagounidis |
Der Internist | 2020 |
Dynamic responses of the haematopoietic stem cell niche to diverse stresses
A Batsivari, ML Haltalli, D Passaro, C Pospori, CL Celso, D Bonnet |
Nature Cell Biology | 2020 |
Inhibition of LSD1 in MDS progenitors restores differentiation of CD141Hi conventional dendritic cells
P Srivastava, SL Tzetzo, EC Gomez, KH Eng, SN Sait, JB Kuechle, PK Singh, KD Jong, KR Wiatrowski, J Peresie, A Dimitroff, ML Lynch, J Wang, SI Abrams, EA Griffiths, MJ Nemeth |
Leukemia | 2020 |
TIFAB Regulates USP15-Mediated p53 Signaling during Stressed and Malignant Hematopoiesis
M Niederkorn, K Hueneman, K Choi, ME Varney, L Romano, MA Pujato, KD Greis, J Inoue, R Meetei, DT Starczynowski |
Cell Reports | 2020 |
Novel combinations to improve hematopoiesis in myelodysplastic syndrome
K Syed, S Naguib, ZJ Liu, L Cimmino, FC Yang |
Stem Cell Research & Therapy | 2020 |
SETD2 deficiency accelerates MDS-associated leukemogenesis via S100a9 in NHD13 mice and predicts poor prognosis in MDS
BY Chen, J Song, CL Hu, SB Chen, Q Zhang, CH Xu, JC Wu, D Hou, M Sun, YL Zhang, N Liu, PC Yu, P Liu, LJ Zong, JY Zhang, RF Dai, F Lan, QH Huang, SJ Zhang, SD Nimer, Z Chen, SJ Chen, XJ Sun, L Wang |
Blood | 2020 |
Genetics of progression from MDS to secondary leukemia
AJ Menssen, MJ Walter |
Blood | 2020 |
Regulation of the Bone Marrow Niche by Inflammation
I Mitroulis, L Kalafati, M Bornhäuser, G Hajishengallis, T Chavakis |
Frontiers in immunology | 2020 |
Severe ineffective erythropoiesis discriminates prognosis in myelodysplastic syndromes: analysis based on 776 patients from a single centre
H Huang, C Xu, J Gao, B Li, T Qin, Z Xu, S Ren, Y Zhang, M Jiao, S Qu, L Pan, N Hu, J Liu, W Cai, Y Zhang, D Wu, P Zhang, RP Gale, G Huang, J Zhou, L Shi, Z Xiao |
Blood Cancer Journal | 2020 |
Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19
A Silvin, N Chapuis, G Dunsmore, AG Goubet, A Dubuisson, L Derosa, C Almire, C Hénon, O Kosmider, N Droin, P Rameau, C Catelain, A Alfaro, C Dussiau, C Friedrich, E Sourdeau, N Marin, TA Szwebel, D Cantin, L Mouthon, D Borderie, M Deloger, D Bredel, S Mouraud, D Drubay, M Andrieu, AS Lhonneur, V Saada, A Stoclin, C Willekens, F Pommeret, F Griscelli, LG Ng, Z Zhang, P Bost, I Amit, F Barlesi, A Marabelle, F Pène, B Gachot, F André, L Zitvogel, F Ginhoux, M Fontenay, E Solary |
Cell | 2020 |
Myeloid-derived suppressor cell cytokine secretion as prognostic factor in myelodysplastic syndromes
D Han, J Tao, R Fu, Z Shao |
Innate immunity | 2020 |
Monocytic myeloid‐derived suppressor cells reflect tuberculosis severity and are influenced by cyclooxygenase‐2 inhibitors
MJ Jørgensen, S Jenum, K Tonby, R Mortensen, G Walzl, ND Plessis, AM DyrholRiise |
Journal of leukocyte biology | 2020 |
The immunology of SARS-CoV-2 infections and vaccines
L Grigoryan, B Pulendran |
Seminars in Immunology | 2020 |
Clinical Response to the CD95-Ligand Inhibitor Asunercept Is Defined by a Pro-Inflammatory Serum Cytokine Profile
A Radujkovic, T Boch, F Nolte, D Nowak, C Kunz, A Gieffers, C Müller-Tidow, P Dreger, WK Hofmann, T Luft |
Cancers | 2020 |
Neutrophil Phenotypes in Coronary Artery Disease
P Maréchal, J Tridetti, M Nguyen, O Wéra, Z Jiang, M Gustin, A Donneau, C Oury, P Lancellotti |
Journal of Clinical Medicine | 2020 |
Hippo kinase loss contributes to del(20q) hematologic malignancies through chronic innate immune activation
SA Stoner, M Yan, KT Liu, KI Arimoto, T Shima, HY Wang, DT Johnson, R Bejar, C Jamieson, KL Guan, DE Zhang |
Blood | 2019 |
Calcium-Binding Proteins of the EF-Hand Superfamily: From Basics to Medical Applications
CW Heizmann |
2019 | |
Perforin and Granzyme B Expressed by Murine Myeloid-Derived Suppressor Cells: A Study on Their Role in Outgrowth of Cancer Cells
I Dufait, J Pardo, D Escors, YD Vlaeminck, H Jiang, M Keyaerts, MD Ridder, K Breckpot |
Cancers | 2019 |
Expression profiling of immune inhibitory Siglecs and their ligands in patients with glioma
KC Santegoets, PR Gielen, C Büll, BM Schulte, ED Kers-Rebel, B Küsters, SA Bossman, M ter Laan, P Wesseling, GJ Adema |
Cancer Immunology, Immunotherapy | 2019 |
Myeloid-Derived Suppressor Cells in Hematologic Diseases: Promising Biomarkers and Treatment Targets
N Bizymi, S Bjelica, AO Kittang, S Mojsilovic, M Velegraki, C Pontikoglou, M Roussel, E Ersvær, JF Santibañez, M Lipoldová, HA Papadaki |
2019 | |
Flaming and fanning: The Spectrum of inflammatory influences in myelodysplastic syndromes
T Banerjee, LM Calvi, MW Becker, JL Liesveld |
Blood Reviews | 2019 |
The inflammatory cytokine profile of myelodysplastic syndromes: A meta-analysis
X Shi, Y Zheng, L Xu, C Cao, B Dong, X Chen |
Medicine | 2019 |
Myeloid Derived Suppressor Cells Expansion Persists After Early ART and May Affect CD4 T Cell Recovery
C Agrati, N Tumino, V Bordoni, C Pinnetti, A Sabatini, A Amendola, I Abbate, P Lorenzini, A Mondi, R Casetti, E Cimini, G Grassi, A Antinori, A Sacchi |
Frontiers in immunology | 2019 |
Myeloid-derived suppressor cells in hematological malignancies: friends or foes
M Lv, K Wang, X Huang |
Journal of Hematology & Oncology | 2019 |
Inflammatory bone marrow microenvironment
NB Leimkühler, RK Schneider |
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program | 2019 |
A New Approach for the Diagnosis of Myelodysplastic Syndrome Subtypes Based on Protein Interaction Analysis
L Chrastinová, O Pastva, M Bocková, NS Lynn, P Šácha, M Hubálek, J Suttnar, R Kotlín, J Štikarová, A Hlaváčková, K Pimková, J Čermák, J Homola, JE Dyr |
Scientific Reports | 2019 |
The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes.
Sallman DA, List A |
Blood | 2019 |
S100A9-induced overexpression of PD-1/PD-L1 contributes to ineffective hematopoiesis in myelodysplastic syndromes.
Cheng P, Eksioglu EA, Chen X, Kandell W, Le Trinh T, Cen L, Qi J, Sallman DA, Zhang Y, Tu N, Adams WA, Zhang C, Liu J, Cleveland JL, List AF, Wei S |
Leukemia | 2019 |
BID-ding on necroptosis in MDS
Croker BA, Kelliher MA |
Blood | 2019 |
The role of innate immunity in MDS pathogenesis
Sallman DA, List A |
HemaSphere | 2019 |
Hypersialylation in Cancer: Modulation of Inflammation and Therapeutic Opportunities
E Rodrigues, M Macauley |
Cancers | 2018 |
Disordered Immune Regulation and its Therapeutic Targeting in Myelodysplastic Syndromes
KS Ivy, PB Ferrell |
Current Hematologic Malignancy Reports | 2018 |
Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes
N Daver, P Boddu, G Garcia-Manero, SS Yadav, P Sharma, J Allison, H Kantarjian |
Leukemia | 2018 |
The bone-marrow niche in MDS and MGUS: implications for AML and MM
IM Ghobrial, A Detappe, KC Anderson, DP Steensma |
Nature Reviews Clinical Oncology | 2018 |
STAT3 in Tumor-Associated Myeloid Cells: Multitasking to Disrupt Immunity
YL Su, S Banerjee, S White, M Kortylewski |
International journal of molecular sciences | 2018 |
Immunomodulatory Function of Myeloid-Derived Suppressor Cells during B Cell-Mediated Immune Responses
B Özkan, H Lim, SG Park |
International journal of molecular sciences | 2018 |
Age-related inflammatory bone marrow microenvironment induces ineffective erythropoiesis mimicking del(5q) MDS
Y Mei, B Zhao, AA Basiorka, J Yang, L Cao, J Zhang, A List, P Ji |
Leukemia | 2018 |
Cancer immune therapy for myeloid malignancies: present and future
MO Holmström, HC Hasselbalch |
Seminars in Immunopathology | 2018 |
Secretory IgM Exacerbates Tumor Progression by Inducing Accumulations of MDSCs in Mice
CH Tang, S Chang, A Hashimoto, YJ Chen, CW Kang, AR Mato, JR Valle, DI Gabrilovich, CC Hu |
Cancer immunology research | 2018 |
Chronic immune response dysregulation in MDS pathogenesis
L Barreyro, TM Chlon, DT Starczynowski |
Blood | 2018 |
The orphan nuclear receptor EAR-2 (NR2F6) inhibits hematopoietic cell differentiation and induces myeloid dysplasia in vivo
CV Ichim, DD Dervovic, LS Chan, CJ Robertson, A Chesney, MD Reis, RA Wells |
Biomarker Research | 2018 |
Clonal Hematopoiesis in Aging.
Park SJ, Bejar R |
Current Stem Cell Reports | 2018 |
Transforming growth factor β1-mediated functional inhibition of mesenchymal stromal cells in myelodysplastic syndromes and acute myeloid leukemia
Geyh S, Rodríguez-Paredes M, Jäger P, Koch A, Bormann F, Gutekunst J, Zilkens C, Germing U, Kobbe G, Lyko F, Haas R, Schroeder T |
Haematologica | 2018 |
KDM6B overexpression activates innate immune signaling and impairs hematopoiesis in mice.
Wei Y, Zheng H, Bao N, Jiang S, Bueso-Ramos CE, Khoury J, Class C, Lu Y, Lin K, Yang H, Ganan-Gomez I, Starczynowski DT, Do KA, Colla S, Garcia-Manero G |
Blood Advances | 2018 |
Novel Strategies for Peptide-Based Vaccines in Hematological Malignancies.
Klausen U, Holmberg S, Holmström MO, Jørgensen NGD, Grauslund JH, Svane IM, Andersen MH |
Frontiers in immunology | 2018 |
The Rising Era of Immune Checkpoint Inhibitors in Myelodysplastic Syndromes.
Chokr N, Patel R, Wattamwar K, Chokr S |
Advances in Hematology | 2018 |
Old Dogs, New Tricks: Revisiting Immune Modulatory Approaches for Myelodysplastic Syndromes.
Götze KS, Platzbecker U |
HemaSphere | 2018 |
Targeting innate immunity to downmodulate adaptive immunity and reverse type 1 diabetes
A Itoh, WM Ridgway |
ImmunoTargets and Therapy | 2017 |
MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia
AR Pyzer, D Stroopinsky, H Rajabi, A Washington, A Tagde, M Coll, J Fung, MP Bryant, L Cole, K Palmer, P Somaiya, RK Leaf, M Nahas, A Apel, S Jain, M McMasters, L Mendez, J Levine, R Joyce, J Arnason, PP Pandolfi, D Kufe, J Rosenblatt, D Avigan |
Blood | 2017 |
Stem and progenitor cell alterations in myelodysplastic syndromes
A Shastri, B Will, U Steidl, A Verma |
Blood | 2017 |
Novel therapeutic approach to improve hematopoiesis in low risk MDS by targeting MDSCs with the Fc-engineered CD33 antibody BI 836858
EA Eksioglu, X Chen, KH Heider, B Rueter, KL McGraw, AA Basiorka, M Wei, A Burnette, P Cheng, J Lancet, R Komrokji, J Djeu, A List, S Wei |
Leukemia | 2017 |
The microenvironment in myelodysplastic syndromes: niche-mediated disease initiation and progression
AJ Li, LM Calvi |
Experimental Hematology | 2017 |
S100A8/A9 increases the mobilization of pro-inflammatory Ly6Chigh monocytes to the synovium during experimental osteoarthritis
NA Cremers, MH van Bosch, S Dalen, ID Ceglie, G Ascone, F de Loo, M Koenders, P der Kraan, A Sloetjes, T Vogl, J Roth, EJ Geven, AB Blom, PL van Lent |
Arthritis Research & Therapy | 2017 |
Immunotherapeutic Concepts to Target Acute Myeloid Leukemia: Focusing on the Role of Monoclonal Antibodies, Hypomethylating Agents and the Leukemic Microenvironment
O Gbolahan, A Zeidan, M Stahl, MA Zaid, S Farag, S Paczesny, H Konig |
International journal of molecular sciences | 2017 |
Pro-inflammatory proteins S100A9 and tumor necrosis factor-α suppress erythropoietin elaboration in myelodysplastic syndromes
T Cluzeau, KL McGraw, B Irvine, E Masala, L Ades, AA Basiorka, J Maciejewski, P Auberger, S Wei, P Fenaux, V Santini, A List |
Haematologica | 2017 |
NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-lymphocyte Responses in Patients with Myelodysplastic Syndrome
EA Griffiths, P Srivastava, J Matsuzaki, Z Brumberger, ES Wang, J Kocent, A Miller, GW Roloff, HY Wong, BE Paluch, LG Lutgen-Dunckley, BL Martens, K Odunsi, AR Karpf, CS Hourigan, MJ Nemeth |
Clinical cancer research | 2017 |
Mass cytometry deep phenotyping of human mononuclear phagocytes and myeloid-derived suppressor cells from human blood and bone marrow.
Roussel M, Ferrell PB Jr, Greenplate AR, Lhomme F, Le Gallou S, Diggins KE, Johnson DB, Irish JM |
Journal of leukocyte biology | 2017 |
骨髓增生异常综合征骨髓微环境异常的研究进展
|
2017 | |
[Research progress of bone marrow microenvironment abnormalities in myelodysplastic syndrome].
Dong PY, Huang LF, Sun HY |
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi | 2017 |
Is Disease-Specific Immunotherapy a Potential Reality for MDS?
Sallman DA, Davila ML |
Clinical Lymphoma, Myeloma & Leukemia | 2017 |
Adaptive NK Cells with Low TIGIT Expression Are Inherently Resistant to Myeloid-Derived Suppressor Cells
D Sarhan, F Cichocki, B Zhang, A Yingst, SR Spellman, S Cooley, MR Verneris, BR Blazar, JS Miller |
Cancer research | 2016 |
Treatment options for patients with myelodysplastic syndromes after hypomethylating agent failure
HE Carraway |
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program | 2016 |
The Role of Toll-Like Receptors in Hematopoietic Malignancies
DA Monlish, ST Bhatt, LG Schuettpelz |
Frontiers in immunology | 2016 |
Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis—Masters of Survival and Clonality?
L Pleyer, P Valent, R Greil |
International journal of molecular sciences | 2016 |
Improving cancer immunotherapy by targeting the STATe of MDSCs
N Haas, C Koning, L Spilgies, IJ de Vries, SV Hato |
OncoImmunology | 2016 |
Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9
RK Schneider, M Schenone, MV Ferreira, R Kramann, CE Joyce, C Hartigan, F Beier, TH Brümmendorf, U Germing, U Platzbecker, G Büsche, R Knüchel, MC Chen, CS Waters, E Chen, LP Chu, CD Novina, RC Lindsley, SA Carr, BL Ebert |
Nature Medicine | 2016 |
Ubiquitination of hnRNPA1 by TRAF6 links chronic innate immune signaling with myelodysplasia
J Fang, LC Bolanos, K Choi, X Liu, S Christie, S Akunuru, R Kumar, D Wang, X Chen, KD Greis, P Stoilov, MD Filippi, JP Maciejewski, G Garcia-Manero, MT Weirauch, N Salomonis, H Geiger, Y Zheng, DT Starczynowski |
Nature Immunology | 2016 |
Context Matters: Distinct Disease Outcomes as a Result of Crebbp Hemizygosity in Different Mouse Bone Marrow Compartments
T Zhou, SN Perez, Z Cheng, MC Kinney, ME Lemieux, LM Scott, VI Rebel, F Bertolini |
PloS one | 2016 |
CD14 Is a Co-Receptor for TLR4 in the S100A9-Induced Pro-Inflammatory Response in Monocytes
Z He, M Riva, P Björk, K Swärd, M Mörgelin, T Leanderson, F Ivars, A Haziot |
PloS one | 2016 |
Down-regulation of EZH2 expression in myelodysplastic syndromes
M Cabrero, Y Wei, H Yang, I Ganan-Gomez, Z Bohannan, S Colla, M Marchesini, GM Bravo, K Takahashi, C Bueso-Ramos, G Garcia-Manero |
Leukemia Research | 2016 |
Unraveling the Pathogenesis of MDS: The NLRP3 Inflammasome and Pyroptosis Drive the MDS Phenotype
DA Sallman, T Cluzeau, AA Basiorka, A List |
Frontiers in Oncology | 2016 |
The Systemic Profile of Soluble Immune Mediators in Patients with Myelodysplastic Syndromes
A Kittang, K Sand, A Brenner, K Rye, Ø Bruserud |
International journal of molecular sciences | 2016 |
Reduced potency of cytotoxic T lymphocytes from patients with high-risk myelodysplastic syndromes
K Sand, J Theorell, Ø Bruserud, YT Bryceson, AO Kittang |
Cancer Immunology, Immunotherapy | 2016 |
Bone Marrow Immunity and Myelodysplasia
C Lambert, Y Wu, C Aanei |
Frontiers in Oncology | 2016 |
Myelodysplastic Syndrome Revealed by Systems Immunology in a Melanoma Patient Undergoing Anti-PD-1 Therapy
AR Greenplate, DB Johnson, M Roussel, MR Savona, JA Sosman, I Puzanov, PB Ferrell, JM Irish |
Cancer immunology research | 2016 |
Mesenchymal stromal cells in myeloid malignancies
T Schroeder, S Geyh, U Germing, R Haas |
Blood Research | 2016 |
The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype
AA Basiorka, KL McGraw, EA Eksioglu, X Chen, J Johnson, L Zhang, Q Zhang, BA Irvine, T Cluzeau, DA Sallman, E Padron, R Komrokji, L Sokol, RC Coll, AA Robertson, MA Cooper, JL Cleveland, LA ONeill, S Wei, AF List |
Blood | 2016 |
Stress and Non-Stress Roles of Inflammatory Signals during HSC Emergence and Maintenance
T Clapes, S Lefkopoulos, E Trompouki |
Frontiers in immunology | 2016 |
The phenotype, development and biological function of myeloid-derived suppressor cells: Molecular regulation of MDSCs
Y Zhao, T Wu, S Shao, B Shi, Y Zhao |
OncoImmunology | 2015 |
IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells
C Schinke, O Giricz, W Li, A Shastri, S Gordon, L Barreryo, T Bhagat, S Bhattacharyya, N Ramachandra, M Bartenstein, A Pellagatti, J Boultwood, A Wickrema, Y Yu, B Will, S Wei, U Steidl, A Verma |
Blood | 2015 |
Inactivation of DAP12 in PMN Inhibits TREM1-Mediated Activation in Rheumatoid Arthritis
X Chen, EA Eksioglu, JD Carter, N Fortenbery, SS Donatelli, J Zhou, J Liu, L Yang, D Gilvary, J Djeu, S Wei, S Papa |
PloS one | 2015 |
Immature myeloid cells directly contribute to skin tumor development by recruiting IL-17-producing CD4+ T cells
ML Ortiz, V Kumar, A Martner, S Mony, L Donthireddy, T Condamine, J Seykora, SC Knight, G Malietzis, GH Lee, M Moorghen, B Lenox, N Luetteke, E Celis, D Gabrilovich |
Journal of Experimental Medicine | 2015 |
Toll-like receptor signaling in hematopoietic homeostasis and the pathogenesis of hematologic diseases
J Cannova, PB S.J., J Zhang |
Frontiers of Medicine | 2015 |
COX-2 promotes metastasis in nasopharyngeal carcinoma by mediating interactions between cancer cells and myeloid-derived suppressor cells
ZL Li, SB Ye, LY OuYang, H Zhang, YS Chen, J He, QY Chen, CN Qian, XS Zhang, J Cui, YX Zeng, J Li |
OncoImmunology | 2015 |
The inflammatory microenvironment in MDS
L Yang, Y Qian, E Eksioglu, PK Epling-Burnette, S Wei |
Cellular and Molecular Life Sciences | 2015 |
Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes
I Gañán-Gómez, Y Wei, DT Starczynowski, S Colla, H Yang, M Cabrero-Calvo, ZS Bohannan, A Verma, U Steidl, G Garcia-Manero |
Leukemia | 2015 |
Myeloid Derived Suppressor Cells in Chronic Myeloid Leukemia
C Giallongo, N Parrinello, MV Brundo, SA Raccuia, MD Rosa, PL Cava, D Tibullo |
Frontiers in Oncology | 2015 |
Revisiting the case for genetically engineered mouse models in human myelodysplastic syndrome research
T Zhou, MC Kinney, LM Scott, SS Zinkel, VI Rebel |
Blood | 2015 |
Biology of the bone marrow microenvironment and myelodysplastic syndromes
EB Rankin, A Narla, JK Park, S Lin, KM Sakamoto |
Molecular Genetics and Metabolism | 2015 |
Loss of Tifab, a del(5q) MDS gene, alters hematopoiesis through derepression of Toll-like receptor-TRAF6 signaling
ME Varney, M Niederkorn, H Konno, T Matsumura, J Gohda, N Yoshida, T Akiyama, S Christie, J Fang, D Miller, A Jerez, A Karsan, JP Maciejewski, RA Meetei, J Inoue, DT Starczynowski |
Journal of Experimental Medicine | 2015 |
Expansion of myeloid derived suppressor cells correlates with number of T regulatory cells and disease progression in myelodysplastic syndrome
AO Kittang, S Kordasti, KE Sand, B Costantini, AM Kramer, P Perezabellan, T Seidl, KP Rye, KM Hagen, A Kulasekararaj, Ø Bruserud, GJ Mufti |
OncoImmunology | 2015 |
Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors
Damiani D, Tiribelli M, Raspadori D, Sirianni S, Meneghel A, Cavalllin M, Michelutti A, Toffoletti E, Geromin A, Simeone E, Bocchia M, Fanin R |
Oncotarget | 2015 |
CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets
MK Gleason, JA Ross, ED Warlick, TC Lund, MR Verneris, A Wiernik, S Spellman, MD Haagenson, AJ Lenvik, MR Litzow, PK Epling-Burnette, BR Blazar, LM Weiner, DJ Weisdorf, DA Vallera, JS Miller |
Blood | 2014 |
Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine Models
L Shen, A Sundstedt, M Ciesielski, KM Miles, M Celander, R Adelaiye, A Orillion, E Ciamporcero, S Ramakrishnan, L Ellis, R Fenstermaker, SI Abrams, H Eriksson, T Leanderson, A Olsson, R Pili |
Cancer immunology research | 2014 |
A phase II multicenter rabbit anti-thymocyte globulin trial in patients with myelodysplastic syndromes identifying a novel model for response prediction
RS Komrokji, AW Mailloux, DT Chen, MA Sekeres, R Paquette, WJ Fulp, C Sugimori, J Paleveda-Pena, JP Maciejewski, AF List, PK Epling-Burnette |
Haematologica | 2014 |
Pulmonary surfactant: an immunological perspective
ZC Chroneos, Z Sever-Chroneos, VL Shepherd |
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology | 2009 |